This, the first of two volumes on personalized medicine in lung cancer, touches on the core issues related to the understanding of lung cancer?statistics and epidemiology of lung cancer?along with the incidence of lung cancer in non-smokers. A major focus of this volume is the state of current therapies against lung cancer?immune, targeted therapies against EGFR TKIs, KRAS, ALK, angiogenesis; the associated challenges, especially resistance mechanisms; and recent progress in targeted drug development based on metal chemistry. Chapters are written by some of the leading experts in the field, who provide a better understanding of lung cancer, the factors that make it lethal, and current research focused on developing personalized treatment plans. With a unique mix of topics, this volume summarizes the current state-of-knowledge on lung cancer and the available therapies.